Neurones (NRO) H1 2026 earnings summary

Executive summary

• Revenue for H1 2026 rose 7.2% year-over-year to €454.8M, with organic growth at 6.9%, accelerating from 2025's 5.8% growth.

• Operating income reached €39.7M (8.7% of revenue), up 19.9% year-over-year from €33.1M in H1 2025.

• Net income was €31.2M (6.9% of revenue), up 16.4% year-over-year, with group share at €25.9M.

• Net cash position at June 30, 2026 was €292.9M, after €33.4M in dividends and €17.1M in share buybacks.

• Workforce averaged 7,329, up from 7,188 in H1 2025; period-end staff was 7,413, up from 7,264.

Financial highlights

• Revenue: €454.8M in H1 2026 vs €424.3M in H1 2025 (+7.2%).

• Operating profit: €39.7M (8.7% margin) in H1 2026, up from €33.1M (7.8%) in H1 2025.

• Net profit after tax: €31.2M (6.9% margin) in H1 2026, up from €26.8M (6.3%) in H1 2025; group share: €25.9M.

• Net cash (excluding IFRS 16): €292.9M at June 30, 2026, up €10.7M after share repurchase and dividend payout.

• EPS (diluted): €1.07 for H1 2026.

Outlook and guidance

• Full-year 2026 revenue expected to exceed €900M.

• Operating margin guidance maintained at approximately 9%.

• AI-driven transformation anticipated to positively impact future activity.